All content on this site is copyright under Creative Commons Attribution - Share Alike license.
FiberCell Systems
While we’re talking about all things Fort Related, there was a press release by TEDCO Wednesday [warning, PDF] and several FredCoBio companies won funding to support product development activities with Ft Detrick scientists.
BioAssay Works, LLC, located in Ijamsville, Md., is working to develop an optimized, sensitive, lateral-flow visual diagnostic test able to detect and differentiate from a single sample multiple pathogenic poxviruses, including variola, vaccinia, and monkeypox. A prototype diagnostic assay will be designed, manufactured, and tested for the ability to accurately identify and discriminate between vaccinia and monkeypox.
APE-Bridgepath Scientific, Inc., located in Frederick, Md., is working to further develop the GeNova Screen, which is a rapid technology for the identification, isolation, and production of antibody-like molecules using a selectable bacterial-surface display system. The GeNova Screen will consist of an engineered bacterial collection in which each bacterium is capable of expressing one of a library of different receptor proteins on its surface. The identified proteins can be used as therapeutics, diagnostics, and research reagents.
CynerGene IDMP, located in Frederick, Md. in the Frederick Innovative Technology Center, is developing, validating and implementing a supplemental diagnosis of Malaria, HIV, and Dengue using CynerGene’s Infectious Disease Multiplex Panel(IDMP) approach. The IDMP will assist existing industries in becoming more productive by creating innovative biosensors which can become rapidly mainstreamed to meet the surging demand of the new market for rapid, accurate, and non-invasive diagnostics.
Imagilin Technology, LLC, located in Frederick, Md., is working to evaluate the effect of Imagilin patented probiotics as a food supplement to enhance the immune responsiveness of guinea pigs upon immunization or challenge with virulent pathogens. This project will demonstrate the ability for the Imagilin patented probiotics to function as biological adjuvant for enhancing immunization of a vaccine.
Interesting that 3/4 of these companies are FITCI graduates.
